Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BYZK4776
| Stock Name / Fund | iShares Healthcare Innovation UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | DRDR(GBX) LSE |
| ETF Ticker | 2B78(EUR) F |
| ETF Ticker | 2B78.DE(EUR) CXE |
| ETF Ticker | DRDR.LS(GBX) CXE |
| ETF Ticker | HEAL.AS(EUR) CXE |
| ETF Ticker | HEAL.LS(USD) CXE |
| ETF Ticker | HEALz(USD) CXE |
| ETF Ticker | HEAL(EUR) ETF Plus |
| ETF Ticker | DRDR.L(GBP) LSE |
Holdings detail for AMLX
| Stock Name | Amylyx Pharmaceuticals Inc |
| Ticker | AMLX(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US0321085088 |
| LEI | 549300N7RNU56EKK7U80 |
Show aggregate AMLX holdings
News associated with AMLX
- Amylyx Pharmaceuticals (NASDAQ:AMLX) Reaches New 1-Year High on Analyst Upgrade
- Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday after The Goldman Sachs Group raised their price target on the stock from $10.00 to $20.00. The Goldman Sachs Group currently has a buy rating on the stock. Amylyx Pharmaceuticals traded as high as $12.40 and last […] - 2025-09-19 02:18:53
- Guggenheim Raises Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $25.00
- Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) had its price objective hoisted by equities researchers at Guggenheim from $17.00 to $25.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target suggests a potential upside of 109.03% from the company’s […] - 2025-09-17 02:46:45
- Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts
- (RTTNews) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives. Amylyx Pharmaceuticals, Amneal Pharmaceuticals, and argenx SE each marked notable gains on Septe - 2025-09-11 06:41:22
- Peek Under The Hood: ITOT Has 12% Upside
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-03 08:00:12
- Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $11.75 Average Target Price from Analysts
- Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) has been assigned an average rating of “Buy” from the thirteen research firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to […] - 2025-08-06 02:31:00
- Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to Hold at Wall Street Zen
- Wall Street Zen upgraded shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday. Several other research analysts also recently weighed in on AMLX. Leerink Partners upgraded shares of Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating […] - 2025-07-21 02:16:48
- Alps Advisors Inc. Grows Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- Alps Advisors Inc. lifted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 22.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 67,597 shares of the company’s stock after buying an additional 12,167 shares during the quarter. Alps Advisors […] - 2025-07-18 04:58:53
- Guggenheim Initiates Coverage on Amylyx Pharmaceuticals (NASDAQ:AMLX)
- Guggenheim began coverage on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) in a report issued on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $17.00 price target on the stock. Guggenheim’s price target indicates a potential upside of 171.57% from the stock’s previous close. AMLX has been the topic […] - 2025-06-26 02:48:52
- 209,708 Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Acquired by Wellington Management Group LLP
- Wellington Management Group LLP acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 209,708 shares of the company’s stock, valued at approximately $793,000. Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. […] - 2025-06-08 05:50:58
- Mackenzie Financial Corp Has $421,000 Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- Mackenzie Financial Corp increased its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 234.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 111,310 shares of the company’s stock after purchasing an additional 78,070 shares during the period. Mackenzie Financial Corp’s holdings in Amylyx Pharmaceuticals were worth $421,000 as […] - 2025-06-04 05:57:00
- Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Two Sigma Advisers LP
- Two Sigma Advisers LP lowered its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 22.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 241,400 shares of the company’s stock after selling 68,100 shares during the quarter. Two Sigma Advisers LP owned […] - 2025-06-02 05:53:04
- State of Wyoming Decreases Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- State of Wyoming decreased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 37.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 16,077 shares of the company’s stock after selling 9,700 shares during the period. State of Wyoming’s holdings in Amylyx Pharmaceuticals were worth $61,000 as of its most recent filing with […] - 2025-05-29 04:50:51
- Jane Street Group LLC Raises Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- Jane Street Group LLC lifted its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 122.4% in the fourth quarter, HoldingsChannel reports. The firm owned 765,475 shares of the company’s stock after purchasing an additional 421,302 shares during the quarter. Jane Street Group LLC’s holdings in Amylyx Pharmaceuticals were worth $2,893,000 at the end […] - 2025-05-14 05:30:54
- Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $16.00
- Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its price objective raised by HC Wainwright from $12.00 to $16.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock. AMLX has been the subject of several other reports. Mizuho upgraded Amylyx Pharmaceuticals from a “neutral” rating to […] - 2025-05-12 05:12:49
- Marshall Wace LLP Decreases Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- Marshall Wace LLP decreased its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 35.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 184,678 shares of the company’s stock after selling 99,308 shares during the quarter. Marshall Wace LLP’s holdings in Amylyx […] - 2025-05-02 05:30:59
- XTX Topco Ltd Purchases 5,704 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- XTX Topco Ltd increased its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 12.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,376 shares of the company’s stock after acquiring an additional 5,704 shares during the period. XTX […] - 2025-04-28 05:48:57
- Renaissance Technologies LLC Has $1.76 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- Renaissance Technologies LLC raised its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 70.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 464,400 shares of the company’s stock after buying an additional 192,600 shares during […] - 2025-04-28 04:44:59
- Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Moderate Buy” by Brokerages
- Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong […] - 2025-04-25 03:12:51
- Federated Hermes Inc. Has $765,000 Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- Federated Hermes Inc. raised its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 8.6% during the 4th quarter, HoldingsChannel reports. The firm owned 202,316 shares of the company’s stock after purchasing an additional 16,030 shares during the quarter. Federated Hermes Inc.’s holdings in Amylyx Pharmaceuticals were worth $765,000 as of its […] - 2025-04-16 05:15:06
- Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $7.33 Average Price Target from Brokerages
- Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued […] - 2025-04-03 02:36:46
- 13,909 Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Bought by EntryPoint Capital LLC
- EntryPoint Capital LLC purchased a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 13,909 shares of the company’s stock, valued at approximately $53,000. Several other hedge funds have […] - 2025-03-31 05:32:51
- Fox Run Management L.L.C. Acquires Shares of 11,788 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
- Fox Run Management L.L.C. bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,788 shares of the company’s stock, valued at approximately $45,000. Several other hedge funds have also modified their […] - 2025-03-30 05:50:47
- Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33
- Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating […] - 2025-02-12 05:00:52
iShares Healthcare Innovation UCITS ETF USD (Acc) AMLX holdings
| Date | Number of AMLX Shares Held | Base Market Value of AMLX Shares | Local Market Value of AMLX Shares | Change in AMLX Shares Held | Change in AMLX Base Value | Current Price per AMLX Share Held | Previous Price per AMLX Share Held |
|---|
| 2025-11-11 (Tuesday) | 90,761 | USD 1,150,849 | USD 1,150,849 | 0 | USD 45,380 | USD 12.68 | USD 12.18 |
| 2025-11-10 (Monday) | 90,761 | USD 1,105,469 | USD 1,105,469 | 0 | USD -11,799 | USD 12.18 | USD 12.31 |
| 2025-11-07 (Friday) | 90,761 | USD 1,117,268 | USD 1,117,268 | 0 | USD -13,614 | USD 12.31 | USD 12.46 |
| 2025-11-06 (Thursday) | 90,761 | USD 1,130,882 | USD 1,130,882 | 0 | USD -70,794 | USD 12.46 | USD 13.24 |
| 2025-11-05 (Wednesday) | 90,761 | USD 1,201,676 | USD 1,201,676 | 0 | USD -45,380 | USD 13.24 | USD 13.74 |
| 2025-11-04 (Tuesday) | 90,761 | USD 1,247,056 | USD 1,247,056 | 0 | USD 12,706 | USD 13.74 | USD 13.6 |
| 2025-11-03 (Monday) | 90,761 | USD 1,234,350 | USD 1,234,350 | 0 | USD -29,951 | USD 13.6 | USD 13.93 |
| 2025-10-31 (Friday) | 90,761 | USD 1,264,301 | USD 1,264,301 | 0 | USD -10,891 | USD 13.93 | USD 14.05 |
| 2025-10-30 (Thursday) | 90,761 | USD 1,275,192 | USD 1,275,192 | 0 | USD 14,522 | USD 14.05 | USD 13.89 |
| 2025-10-29 (Wednesday) | 90,761 | USD 1,260,670 | USD 1,260,670 | 0 | USD -39,028 | USD 13.89 | USD 14.32 |
| 2025-10-28 (Tuesday) | 90,761 | USD 1,299,698 | USD 1,299,698 | 0 | USD 8,169 | USD 14.32 | USD 14.23 |
| 2025-10-27 (Monday) | 90,761 | USD 1,291,529 | USD 1,291,529 | 0 | USD 5,446 | USD 14.23 | USD 14.17 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of AMLX by Blackrock for IE00BYZK4776
Show aggregate share trades of AMLX| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-24 | SELL | -774 | 14.170 | 14.609 | 14.565 | USD -11,273 | 10.52 Loss of -3,129 on sale |
| 2025-09-11 | BUY | 391 | 11.840 | 12.090 | 12.065 | USD 4,717 | 7.36 |
| 2025-07-08 | SELL | -390 | 6.980 | 7.000 | 6.998 | USD -2,729 | 6.29 Loss of -278 on sale |
| 2025-06-25 | SELL | -404 | 6.260 | 6.500 | 6.476 | USD -2,616 | 5.71 Loss of -307 on sale |
| 2025-06-23 | SELL | -404 | 5.020 | 5.090 | 5.083 | USD -2,054 | 0.00 Loss of -2,054 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of AMLX
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 418,771 | 823 | 941,620 | 44.5% |
| 2025-09-18 | 402,894 | 21 | 802,647 | 50.2% |
| 2025-09-17 | 546,593 | 0 | 1,358,029 | 40.2% |
| 2025-09-16 | 396,759 | 0 | 530,067 | 74.9% |
| 2025-09-15 | 310,521 | 0 | 564,748 | 55.0% |
| 2025-09-12 | 449,853 | 0 | 944,784 | 47.6% |
| 2025-09-11 | 462,717 | 3,900 | 1,138,052 | 40.7% |
| 2025-09-10 | 1,134,606 | 1,000 | 3,410,961 | 33.3% |
| 2025-09-09 | 141,102 | 42 | 469,195 | 30.1% |
| 2025-09-08 | 327,586 | 0 | 601,463 | 54.5% |
| 2025-09-05 | 309,419 | 0 | 808,837 | 38.3% |
| 2025-09-04 | 148,051 | 0 | 221,235 | 66.9% |
| 2025-09-03 | 335,944 | 0 | 863,698 | 38.9% |
| 2025-09-02 | 227,552 | 39 | 656,614 | 34.7% |
| 2025-08-29 | 536,975 | 0 | 713,581 | 75.3% |
| 2025-08-28 | 521,138 | 100 | 730,229 | 71.4% |
| 2025-08-27 | 439,816 | 1 | 1,013,439 | 43.4% |
| 2025-08-26 | 154,507 | 1,030 | 440,623 | 35.1% |
| 2025-08-25 | 396,683 | 0 | 1,033,823 | 38.4% |
| 2025-08-22 | 581,918 | 0 | 1,302,177 | 44.7% |
| 2025-08-21 | 261,686 | 0 | 618,491 | 42.3% |
| 2025-08-20 | 133,178 | 1,236 | 594,728 | 22.4% |
| 2025-08-19 | 150,106 | 80 | 332,808 | 45.1% |
| 2025-08-18 | 124,254 | 0 | 479,866 | 25.9% |
| 2025-08-15 | 105,866 | 0 | 229,968 | 46.0% |
| 2025-08-14 | 111,949 | 1,672 | 215,637 | 51.9% |
| 2025-08-13 | 131,895 | 0 | 266,239 | 49.5% |
| 2025-08-12 | 116,709 | 0 | 254,028 | 45.9% |
| 2025-08-11 | 126,534 | 0 | 177,291 | 71.4% |
| 2025-08-08 | 168,225 | 700 | 340,423 | 49.4% |
| 2025-08-07 | 254,191 | 2,215 | 370,441 | 68.6% |
| 2025-08-06 | 251,558 | 0 | 374,068 | 67.2% |
| 2025-08-05 | 163,536 | 0 | 233,083 | 70.2% |
| 2025-08-04 | 168,808 | 200 | 349,982 | 48.2% |
| 2025-08-01 | 346,767 | 100 | 629,488 | 55.1% |
| 2025-07-31 | 290,813 | 69 | 435,324 | 66.8% |
| 2025-07-30 | 178,813 | 0 | 305,786 | 58.5% |
| 2025-07-29 | 202,900 | 0 | 299,315 | 67.8% |
| 2025-07-28 | 209,881 | 4,503 | 293,344 | 71.5% |
| 2025-07-25 | 106,988 | 0 | 195,074 | 54.8% |
| 2025-07-24 | 134,964 | 111 | 234,001 | 57.7% |
| 2025-07-23 | 342,638 | 5,701 | 1,063,335 | 32.2% |
| 2025-07-22 | 194,980 | 0 | 381,408 | 51.1% |
| 2025-07-21 | 504,775 | 125 | 1,020,597 | 49.5% |
| 2025-07-18 | 182,513 | 8,561 | 367,854 | 49.6% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.